WordNet

travel or traverse (a distance); "This car does 150 miles per hour"; "We did 6 miles on our hike every day"
the syllable naming the first (tonic) note of any major scale in solmization (同)doh, ut
proceed or get along; "How is she doing in her new job?"; "How are you making out in graduate school?"; "Hes come a long way" (同)fare, make_out, come, get along
create or design, often in a certain way; "Do my room in blue"; "I did this piece in wood to express my love for the forest" (同)make
carry on or function; "We could do with a little more help around here" (同)manage
get (something) done; "I did my job" (同)perform
treat with an agent; add (an agent) to; "The ray dosed the paint"
the quantity of an active agent (substance or radiation) taken in or absorbed at any one time (同)dosage
a measured portion of medicine taken at any one time (同)dosage
abnormal redness of the skin resulting from dilation of blood vessels (as in sunburn or inflammation)
treated with some kind of application; "a mustache dosed with bear grease"

PrepTutorEJDIC

《疑問文・否定文を作る》 / 《否定命令文を作る》 / 《助動詞とbe動詞のどちらも含まない文に用いて付加疑問を作る》 / 《強意語として》 / 《文》《助動詞とbe動詞のどちらも含まない文に用いて倒置文を作る》 / 《あいづちを打つ場合に》 / 《先行する動詞またはそれを含む述部の代用》 / 《so,nor,neitherで始まる簡略文で》 / …‘を'『する』,行う,果たす / 《通例have done,時にbe doneの形で》…‘を'『終える』,済ませる / …‘を'作る,作り出す / …‘を'『処理する』,整える,片付ける / 〈学課〉‘を'『勉強する』,専攻する / 〈利益・害など〉‘を'与える,もたらす / 〈人〉‘に'『役立つ』,用が足りる(serve) / …の速度で進む,距離を行く / …‘を'見物する / 〈劇〉‘を'上演する;…‘の'役を演じる / …の役目(仕事)をする / 《おもに英》…‘を'だます,かつぐ / 《話》…をへとへとにさせる / 『する』;活動する / 《通例have done,時にbe doneの形で》(…を)『終える』,済ます《+『with』+『名』》 / 〈事が〉『運ぶ』;〈人が〉暮らしていく,健康である / 〈物が〉(…に)『間に合う』,十分である;〈人が〉(…に)役に立つ,向く《+『for』+『名』》 / 《複数形で》すべきこと / 〈C〉《おもに英》大宴会,大パーティー / 〈C〉《英話》詐欺,ぺてん
ド(全音階の第1音)
(おもに飲み薬1回分の)『服用量』 / (痛いこと・いやなことの)1回分,一定量 / (人などが受ける放射線の)線量 / 性病 / (…を)…‘に'投薬する,服用させる《+『名』+『with』+『名』》
紅斑(こうはん)(炎症などにより皮膚が異常に赤くなること)

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 従来の癌の化学療法による皮膚合併症 cutaneous complications of conventional chemotherapy agents
2. 非HIV感染患者におけるスルホンアミドアレルギー sulfonamide allergy in non hiv infected patients
3. バンコマイシン過敏症 vancomycin hypersensitivity
4. 上皮成長因子受容体（EGFR）阻害剤投与に続発するざ瘡様発疹 acneiform eruption secondary to epidermal growth factor receptor egfr inhibitors
5. 分子標的剤およびその他の生物製剤を用いた癌治療による皮膚合併症 cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy

English Journal

Concurrent dendritic cell vaccine and strontium-89 radiation therapy in the management of multiple bone metastases.

Liu J1, Li J, Fan Y, Chang K, Yang X, Zhu W, Wu X, Pang Y.
Irish journal of medical science.Ir J Med Sci.2015 Jun;184(2):457-61. doi: 10.1007/s11845-014-1145-9. Epub 2014 May 30.
BACKGROUND: In addition to its direct cytotoxic effects, radiation therapy renders tumor cells more susceptible to T cell-mediated cytotoxicity by modulating cell surface molecules involved in antigen presentation. The purpose of the present study was to determine the benefit of combined 89Sr radiat
PMID 24876093

Adalimumab for the Treatment of Japanese Patients With Intestinal Behçet's Disease.

Tanida S1, Inoue N2, Kobayashi K3, Naganuma M2, Hirai F4, Iizuka B5, Watanabe K6, Mitsuyama K7, Inoue T8, Ishigatsubo Y9, Suzuki Y10, Nagahori M11, Motoya S12, Nakamura S13, Arora V14, Robinson AM14, Thakkar RB14, Hibi T15.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.Clin Gastroenterol Hepatol.2015 May;13(5):940-948.e3. doi: 10.1016/j.cgh.2014.08.042. Epub 2014 Sep 19.
BACKGROUND & AIMS: Behçet's disease is a chronic, relapsing inflammatory disease that can involve the mouth, skin, eyes, genitals, and intestines. Active intestinal Behçet's disease can be complicated by gastrointestinal (GI) bleeding and perforation. We performed a multicenter, open-label, un
PMID 25245624

Switch from oral pramipexole or ropinirole to rotigotine transdermal system in advanced Parkinson's disease: an open-label study.

Chung SJ1, Kim JM, Kim JW, Jeon BS, Singh P, Thierfelder S, Ikeda J, Bauer L; Asia Pacific Rotigotine Switching Study Group.
Expert opinion on pharmacotherapy.Expert Opin Pharmacother.2015 May;16(7):961-70. doi: 10.1517/14656566.2015.1030336. Epub 2015 Apr 6.
OBJECTIVE: Investigate safety, feasibility and efficacy of switching therapy in patients with advanced-stage Parkinson's disease (PD) inadequately controlled with pramipexole (≤ 3.5 mg/day) or ropinirole (≤ 14 mg/day) to rotigotine transdermal system (≤ 14 mg/24 h; dose adjustments ≤ 16 mg/2
PMID 25846031